The estimated Net Worth of Mara G. Aspinall is at least 2.17 百万$ dollars as of 23 May 2024. Ms. Aspinall owns over 8,636 units of Castle Biosciences stock worth over 1,369,633$ and over the last 10 years she sold CSTL stock worth over 494,800$. In addition, she makes 302,714$ as Independent Director at Castle Biosciences.
Mara has made over 11 trades of the Castle Biosciences stock since 2017, according to the Form 4 filled with the SEC. Most recently she exercised 8,636 units of CSTL stock worth 267,975$ on 23 May 2024.
The largest trade she's ever made was exercising 8,636 units of Castle Biosciences stock on 23 May 2024 worth over 267,975$. On average, Mara trades about 1,037 units every 65 days since 2014. As of 23 May 2024 she still owns at least 44,139 units of Castle Biosciences stock.
You can see the complete history of Ms. Aspinall stock trades at the bottom of the page.
Mara Glickman Aspinall serves as Independent Director of the Company. Ms. Aspinall has served as Managing Director of BlueStone Venture Partners, a life science-focused venture capital firm, since December 2017. Since June 2014, Ms. Aspinall has served as the Managing Member of Health Catalysts Group, a consulting firm that focuses on growth of early-stage life science and technology companies. From September 2011 until June 2014, Ms. Aspinall served as the President and Chief Executive Officer of the Ventana Medical Systems and the Global Head of Roche Tissue Diagnostics, a global leader in the development and commercialization of tissue-based cancer diagnostics. Prior to 2011, Ms. Aspinall served as President of Genzyme Pharmaceuticals and Genzyme Genetics. Ms. Aspinall currently serves as a director of Allscripts Healthcare Solutions, Orasure Technologies and UK-based company Abcam plc., along with other privately held healthcare technology and medical insurance companies. Ms. Aspinall holds a B.A. degree in International Relations from Tufts University and an MBA from Harvard Business School. Ms. Aspinall is certified in board oversight of cybersecurity from the National Association of Corporate Directors and Carnegie Mellon University.
As the Independent Director of Castle Biosciences, the total compensation of Mara Aspinall at Castle Biosciences is 302,714$. There are 5 executives at Castle Biosciences getting paid more, with Derek Maetzold having the highest compensation of 4,132,350$.
Mara Aspinall is 57, she's been the Independent Director of Castle Biosciences since 2015. There are 7 older and 6 younger executives at Castle Biosciences. The oldest executive at Castle Biosciences, Inc. is David Kabakoff, 72, who is the Independent Director.
Mara's mailing address filed with the SEC is C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD, TX, 77546.
Over the last 5 years, insiders at Castle Biosciences have traded over 378,509,770$ worth of Castle Biosciences stock and bought 782,652 units worth 12,524,690$ . The most active insiders traders include Daniel Bradbury、Derek J Maetzold、Joseph C. Iii Cook. On average, Castle Biosciences executives and independent directors trade stock every 6 days with the average trade being worth of 632,640$. The most recent stock trade was executed by Derek J Maetzold on 9 September 2024, trading 2,586 units of CSTL stock currently worth 76,184$.
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Castle Biosciences executives and other stock owners filed with the SEC include: